Incyte pays $45mm up front for rights to Calithera's arginase inhibitor
Incyte Corp. licensed global rights to develop and sell Calithera Biosciences Inc.’s arginase inhibitor CB1158 in hematology and oncology indications. Incyte paid $45mm up front and made an $8mm equity investment through the purchase of 1.7mm Calithera common shares at $4.65 (a slight premium).
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.